FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2596573982> ?p ?o ?g. }

• W2596573982 endingPage "29201" @default.
• W2596573982 startingPage "29187" @default.
• W2596573982 abstract "// Emily-Marie Latuske 1 , Hauke Stamm 1 , Marianne Klokow 1 , Gabi Vohwinkel 1 , Jana Muschhammer 1 , Carsten Bokemeyer 1 , Manfred Jücker 2 , Maxim Kebenko 1 , Walter Fiedler 1 , Jasmin Wellbrock 1 1 Department of Oncology, Hematology and Bone Marrow Transplantation with Section Pneumology, Hubertus Wald University Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany 2 Institute of Biochemistry and Signal Transduction, University Medical Center Hamburg-Eppendorf, Hamburg, Germany Correspondence to: Walter Fiedler, email: fiedler@uke.de Keywords: Hedgehog, non-canonical, GLI, FLT3, AML Received: July 22, 2016      Accepted: February 20, 2017      Published: March 16, 2017 ABSTRACT Activation of the Hedgehog pathway has been implicated in the pathogenesis of several tumor types including myeloid leukemia. Previously we demonstrated that overexpression of Hedgehog downstream mediators GLI1/2 confers an adverse prognosis to patients with acute myeloid leukemia (AML) and is correlated with a FLT3 mutated status. To analyze a possible non-canonical activation of the Hedgehog pathway via FLT3 and PI3K, we performed blocking experiments utilizing inhibitors for FLT3 (sunitinib), PI3K (PF-04691502) and GLI1/2 (GANT61) in FLT3-mutated and FLT3 wildtype AML cell lines and primary blasts. Combination of all three compounds had stronger anti-leukemic effects in FLT3-mutated compared to FLT3 wildtype AML cells in vitro . Interestingly, the colony growth of normal CD34 + cells from healthy donors was not impeded by the triple inhibitor combination possibly opening a therapeutic window for the clinical use of inhibitor combinations. Besides, combined treatment with sunitinib, PF-04691502 and GANT61 significantly prolonged the survival of mice transplanted with FLT3-mutated MV4-11 cells compared to the single agent treatments. Furthermore, the inhibition of FLT3 and PI3K resulted in reduced GLI protein expression and promotor activity in FLT3-mutated but not in FLT3 wildtype AML cell lines in western blotting and GLI1/2 promoter assays supporting our hypothesis of non-canonical GLI activation via FLT3. In summary, FLT3-mutated in contrast to FLT3 wildtype cells or normal human hematopoietic progenitor cells are exquisitely sensitive to combined inhibition by FLT3, PI3K and GLI1/2 overcoming some of the limitations of current FLT3 directed therapy in AML. The development of GLI1/2 inhibitors is highly desirable." @default.
• W2596573982 created "2017-03-23" @default.
• W2596573982 creator A5006963992 @default.
• W2596573982 creator A5033422703 @default.
• W2596573982 creator A5057509966 @default.
• W2596573982 creator A5058089589 @default.
• W2596573982 creator A5074106380 @default.
• W2596573982 creator A5078383767 @default.
• W2596573982 creator A5078834232 @default.
• W2596573982 creator A5084039929 @default.
• W2596573982 creator A5086135974 @default.
• W2596573982 creator A5086331329 @default.
• W2596573982 date "2017-03-16" @default.
• W2596573982 modified "2023-10-12" @default.
• W2596573982 title "Combined inhibition of GLI and FLT3 signaling leads to effective anti-leukemic effects in human acute myeloid leukemia" @default.
• W2596573982 cites W1500827124 @default.
• W2596573982 cites W1527009475 @default.
• W2596573982 cites W1935464246 @default.
• W2596573982 cites W1965568759 @default.
• W2596573982 cites W1970915933 @default.
• W2596573982 cites W1978331435 @default.
• W2596573982 cites W1985525573 @default.
• W2596573982 cites W1986357982 @default.
• W2596573982 cites W1987860480 @default.
• W2596573982 cites W1992945290 @default.
• W2596573982 cites W1993300766 @default.
• W2596573982 cites W1995143994 @default.
• W2596573982 cites W1996307710 @default.
• W2596573982 cites W1997379399 @default.
• W2596573982 cites W2002962363 @default.
• W2596573982 cites W2009886857 @default.
• W2596573982 cites W2010237337 @default.
• W2596573982 cites W2015303096 @default.
• W2596573982 cites W2016883830 @default.
• W2596573982 cites W2030643315 @default.
• W2596573982 cites W2038824910 @default.
• W2596573982 cites W2048167482 @default.
• W2596573982 cites W2051120887 @default.
• W2596573982 cites W2051956921 @default.
• W2596573982 cites W2062729664 @default.
• W2596573982 cites W2063981273 @default.
• W2596573982 cites W2076922627 @default.
• W2596573982 cites W2088811912 @default.
• W2596573982 cites W2090176557 @default.
• W2596573982 cites W2092021778 @default.
• W2596573982 cites W2092536825 @default.
• W2596573982 cites W2094123668 @default.
• W2596573982 cites W2099377536 @default.
• W2596573982 cites W2100868792 @default.
• W2596573982 cites W2106533048 @default.
• W2596573982 cites W2106912046 @default.
• W2596573982 cites W2107503279 @default.
• W2596573982 cites W2108707301 @default.
• W2596573982 cites W2110135410 @default.
• W2596573982 cites W2112414163 @default.
• W2596573982 cites W2116936012 @default.
• W2596573982 cites W2120335150 @default.
• W2596573982 cites W2121017846 @default.
• W2596573982 cites W2123811193 @default.
• W2596573982 cites W2125877707 @default.
• W2596573982 cites W2129685249 @default.
• W2596573982 cites W2134953352 @default.
• W2596573982 cites W2153345005 @default.
• W2596573982 cites W2153988344 @default.
• W2596573982 cites W2155704762 @default.
• W2596573982 cites W2155715347 @default.
• W2596573982 cites W2159956387 @default.
• W2596573982 cites W2164886552 @default.
• W2596573982 cites W2168373302 @default.
• W2596573982 cites W2171484579 @default.
• W2596573982 cites W2178741632 @default.
• W2596573982 cites W2240399463 @default.
• W2596573982 cites W2312048098 @default.
• W2596573982 cites W2338801484 @default.
• W2596573982 cites W2511418953 @default.
• W2596573982 cites W2556588269 @default.
• W2596573982 cites W2980055023 @default.
• W2596573982 doi "https://doi.org/10.18632/oncotarget.16304" @default.
• W2596573982 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5438723" @default.
• W2596573982 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28418873" @default.
• W2596573982 hasPublicationYear "2017" @default.
• W2596573982 type Work @default.
• W2596573982 sameAs 2596573982 @default.
• W2596573982 citedByCount "27" @default.
• W2596573982 countsByYear W25965739822018 @default.
• W2596573982 countsByYear W25965739822019 @default.
• W2596573982 countsByYear W25965739822020 @default.
• W2596573982 countsByYear W25965739822021 @default.
• W2596573982 countsByYear W25965739822022 @default.
• W2596573982 countsByYear W25965739822023 @default.
• W2596573982 crossrefType "journal-article" @default.
• W2596573982 hasAuthorship W2596573982A5006963992 @default.
• W2596573982 hasAuthorship W2596573982A5033422703 @default.
• W2596573982 hasAuthorship W2596573982A5057509966 @default.
• W2596573982 hasAuthorship W2596573982A5058089589 @default.
• W2596573982 hasAuthorship W2596573982A5074106380 @default.
• W2596573982 hasAuthorship W2596573982A5078383767 @default.
• W2596573982 hasAuthorship W2596573982A5078834232 @default.

• next